miR-5193 + miR-149-5p

miR-5193 + miR-149-5p is an experimental combination of two synthetic microRNAs (miRNAs) used in preclinical research as a gene therapy approach for cancer treatment. Both are tumor-suppressive non-coding RNAs that regulate gene expression post-transcriptionally. In recent studies, these two miRNAs have been co-delivered using natural killer cell-derived extracellular vesicles (NK-EVs) to target key oncogenic pathways and immune checkpoints in lung cancer models resistant to EGFR tyrosine kinase inhibitors (TKIs), such as Osimertinib. The combination acts by downregulating targets including PD-L1/PD-1 axis and FOXM1, leading to enhanced apoptosis, immune checkpoint inhibition, and anti-inflammatory effects. In vitro and in vivo data show significant reduction in tumor cell viability and tumor volume when combined with chemotherapy agents like carboplatin[1][6][7]. Individually, both miRNAs have demonstrated anti-tumor activity across several cancers by suppressing proliferation, migration, invasion (e.g., via TRIM11 for prostate cancer), modulating immune response (e.g., PD-L1 suppression), and promoting apoptosis[2][4][6]. This combination is currently at the preclinical research stage.

Other names

microRNA 5193 + microRNA 149-5phsa-miR-5193 + hsa-miR-149-5p